HLA-J, a Non-Pseudogene as a New Prognostic Marker for Therapy Response and Survival in Breast Cancer

Abstract The human leukocyte antigen (HLA) genes are cell-surface proteins, essential for immune cell interaction. HLA-G is known for their high immunosuppressive effect and its potential as predictive marker in breast cancer. However, nothing is known about the HLA-J and its immunosuppressive, prognostic and predictive features, as it is assumed to be a “pseudogene” by in silico sequence interpretation. HLA-J, ESR1, ERBB2, KRT5 and KRT20 mRNA expression were analysed in 29 fresh frozen breast cancer biopsies and their corresponding resectates obtained from patients treated with neoadjuvant chemotherapy (NACT). mRNA was analysed with gene specific TaqMan-based Primer/Probe sets and normalized to Calmodulin 2. All breast cancer samples did express HLA-J and frequently increased HLA-J mRNA levels after NACT. HLA-J mRNA was significantly associated with overexpression of the ESR1 mRNA status (Spearman ρ 0,5679; p = 0.0090) and KRT5 mRNA (Spearman ρ 0,6121; p = 0.0041) in breast cancer core biopsies and dominated in luminal B subtype. Kaplan Meier analysis revealed that an increase of HLA-J mRNA expression after NACT had worse progression free survival (p = 0,0096), indicating a counterreaction of tumor tissues presumably to prevent elimination by enhanced immune infiltration induced by NACT. This counterreaction is associated with worse prognosis. To our knowledge this is the first study identifying HLA-J as a new predictive marker in breast cancer being involved in immune evasion mechanisms.

[1]  R. Wirtz,et al.  European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment , 2019, International journal of molecular sciences.

[2]  L. Patrushev,et al.  Pseudogenes as Functionally Significant Elements of the Genome , 2018, Biochemistry (Moscow).

[3]  A. Lin,et al.  Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges , 2018, Front. Immunol..

[4]  M. Lux,et al.  TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes , 2018, Geburtshilfe und Frauenheilkunde.

[5]  Wenfu Zhou,et al.  Predictive value of different proportion of lesion HLA-G expression in colorectal cancer , 2017, Oncotarget.

[6]  P. Ferrari,et al.  Prognostic and predictive biomarkers in breast cancer: Past, present and future. , 2017, Seminars in cancer biology.

[7]  G. Maddern,et al.  Soluble HLA‐G is a differential prognostic marker in sequential colorectal cancer disease stages , 2017, International journal of cancer.

[8]  Frank Noé,et al.  Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation , 2017, Front. Immunol..

[9]  Arun Ahuja,et al.  Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer , 2016, BMC Cancer.

[10]  R. Kimmig,et al.  The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients. , 2016, Human immunology.

[11]  J. Isola,et al.  Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry , 2016, Breast Cancer Research and Treatment.

[12]  A. Fusco,et al.  HMGA1-pseudogenes and cancer , 2016, Oncotarget.

[13]  Yong-Chen Lu,et al.  Cancer immunotherapy targeting neoantigens. , 2016, Seminars in immunology.

[14]  P. Moreau,et al.  Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment , 2015, Oncotarget.

[15]  A. Lin,et al.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy , 2015, Molecular medicine.

[16]  Amy R. Peck,et al.  Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism , 2015, Oncogene.

[17]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[18]  K. Morris,et al.  Not so pseudo anymore: pseudogenes as therapeutic targets. , 2013, Pharmacogenomics.

[19]  V. Nekljudova,et al.  RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  R. Wirtz,et al.  Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research , 2012, Virchows Archiv.

[21]  Hong Yang,et al.  Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. , 2012, Human immunology.

[22]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Neefjes,et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation , 2011, Nature Reviews Immunology.

[24]  K. Horwitz,et al.  Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers , 2011, Breast Cancer Research and Treatment.

[25]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Denkert,et al.  Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) , 2011, Breast Cancer Research and Treatment.

[27]  I. Shih,et al.  HLA-G and immune evasion in cancer cells. , 2010, Journal of the Formosan Medical Association = Taiwan yi zhi.

[28]  Hong Yang,et al.  HLA-G Expression in Human Breast Cancer: Implications for Diagnosis and Prognosis, and Effect on Allocytotoxic Lymphocyte Response After Hormone Treatment In Vitro , 2010, Annals of Surgical Oncology.

[29]  K. Horwitz,et al.  Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts , 2008, Proceedings of the National Academy of Sciences.

[30]  M. Kozak,et al.  Regulation of translation via mRNA structure in prokaryotes and eukaryotes. , 2005, Gene.

[31]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[32]  J. Dausset,et al.  Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. , 2001, Transplantation proceedings.

[33]  A. Hughes,et al.  Origin and evolution of HLA class I pseudogenes. , 1995, Molecular biology and evolution.

[34]  M. Kaufmann,et al.  Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .

[35]  P. Parham,et al.  HLA-J, a second inactivated class I HLA gene related to HLA-G and HLA-A. Implications for the evolution of the HLA-A-related genes. , 1992, Journal of immunology.

[36]  M. Kozak,et al.  An analysis of vertebrate mRNA sequences: intimations of translational control , 1991, The Journal of cell biology.

[37]  N. Arnheim,et al.  Structure and evolution of human and African ape rDNA pseudogenes. , 1983, Molecular biology and evolution.

[38]  James Robinson,et al.  The IPD Databases: Cataloguing and Understanding Allele Variants. , 2018, Methods in molecular biology.

[39]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.